1
|
Rombaut D, Lefèvre C, Rached T, Bondu S, Letessier A, Mangione RM, Farhat B, Lesieur-Pasquier A, Castillo-Guzman D, Boussaid I, Friedrich C, Tourville A, De Carvalho M, Levavasseur F, Leduc M, Le Gall M, Battault S, Temple M, Houy A, Bouscary D, Willems L, Park S, Raynaud S, Cluzeau T, Clappier E, Fenaux P, Adès L, Margueron R, Wassef M, Alsafadi S, Chapuis N, Kosmider O, Solary E, Constantinou A, Stern MH, Droin N, Palancade B, Miotto B, Chédin F, Fontenay M. Accelerated DNA replication fork speed due to loss of R-loops in myelodysplastic syndromes with SF3B1 mutation. Nat Commun 2024; 15:3016. [PMID: 38589367 PMCID: PMC11001894 DOI: 10.1038/s41467-024-46547-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2022] [Accepted: 02/29/2024] [Indexed: 04/10/2024] Open
Abstract
Myelodysplastic syndromes (MDS) with mutated SF3B1 gene present features including a favourable outcome distinct from MDS with mutations in other splicing factor genes SRSF2 or U2AF1. Molecular bases of these divergences are poorly understood. Here we find that SF3B1-mutated MDS show reduced R-loop formation predominating in gene bodies associated with intron retention reduction, not found in U2AF1- or SRSF2-mutated MDS. Compared to erythroblasts from SRSF2- or U2AF1-mutated patients, SF3B1-mutated erythroblasts exhibit augmented DNA synthesis, accelerated replication forks, and single-stranded DNA exposure upon differentiation. Importantly, histone deacetylase inhibition using vorinostat restores R-loop formation, slows down DNA replication forks and improves SF3B1-mutated erythroblast differentiation. In conclusion, loss of R-loops with associated DNA replication stress represents a hallmark of SF3B1-mutated MDS ineffective erythropoiesis, which could be used as a therapeutic target.
Collapse
Affiliation(s)
- David Rombaut
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
- Laboratoire d'excellence du Globule Rouge GR-Ex, Université Paris Cité, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Carine Lefèvre
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
- Laboratoire d'excellence du Globule Rouge GR-Ex, Université Paris Cité, Paris, France
| | - Tony Rached
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Sabrina Bondu
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Anne Letessier
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
| | | | - Batoul Farhat
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Auriane Lesieur-Pasquier
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Daisy Castillo-Guzman
- Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, CA, USA
| | - Ismael Boussaid
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Chloé Friedrich
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Aurore Tourville
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Magali De Carvalho
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Françoise Levavasseur
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Marjorie Leduc
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Platform Proteom'IC, Université Paris Cité, Institut Cochin, Paris, France
| | - Morgane Le Gall
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Platform Proteom'IC, Université Paris Cité, Institut Cochin, Paris, France
| | - Sarah Battault
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
| | - Marie Temple
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Alexandre Houy
- Institut Curie, PSL Research University, Sorbonne University, INSERM U830, DNA repair and uveal melanoma, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France
| | - Didier Bouscary
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Clinical Department of Hematology, Paris, France
| | - Lise Willems
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Clinical Department of Hematology, Paris, France
| | - Sophie Park
- Department of Hematology, Centre Hospitalier Universitaire, Université de Grenoble Alpes, Grenoble, France
| | - Sophie Raynaud
- Laboratory of Hematology, Université Côte d'Azur, Centre Hospitalier Universitaire, Nice, France
| | - Thomas Cluzeau
- Clinical Department of Hematology, Université Côte d'Azur, Centre Hospitalier Universitaire, Nice, France
| | - Emmanuelle Clappier
- Assistance Publique-Hôpitaux de Paris.Nord-Université Paris Cité, Saint-Louis Hospital, Laboratory of Hematology, Paris, France
| | - Pierre Fenaux
- Assistance Publique-Hôpitaux de Paris.Nord-Université Paris Cité, Saint-Louis Hospital, Service Hématologie Séniors, Paris, France
| | - Lionel Adès
- Assistance Publique-Hôpitaux de Paris.Nord-Université Paris Cité, Saint-Louis Hospital, Service Hématologie Séniors, Paris, France
| | - Raphael Margueron
- Institut Curie, Paris Sciences Lettres Research University, Sorbonne University, INSERM U934, UMR3215, Paris, France
| | - Michel Wassef
- Institut Curie, Paris Sciences Lettres Research University, Sorbonne University, INSERM U934, UMR3215, Paris, France
| | - Samar Alsafadi
- Institut Curie, PSL Research University, Sorbonne University, INSERM U830, DNA repair and uveal melanoma, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France
| | - Nicolas Chapuis
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Olivier Kosmider
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France
| | - Eric Solary
- Institut Gustave Roussy, INSERM 1287, Université Paris Saclay, Villejuif, France
| | - Angelos Constantinou
- Institut de Génétique Humaine, Centre National de la Recherche Scientifique, Université de Montpellier, Montpellier, France
| | - Marc-Henri Stern
- Institut Curie, PSL Research University, Sorbonne University, INSERM U830, DNA repair and uveal melanoma, Equipe labellisée par la Ligue Nationale contre le Cancer, Paris, France
| | - Nathalie Droin
- Institut Gustave Roussy, INSERM 1287, Université Paris Saclay, Villejuif, France
| | - Benoit Palancade
- Université Paris Cité, CNRS, Institut Jacques Monod, Paris, France
| | - Benoit Miotto
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France
| | - Frédéric Chédin
- Department of Molecular and Cellular Biology and Genome Center, University of California, Davis, CA, USA
| | - Michaela Fontenay
- Université Paris Cité, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Institut Cochin, Paris, France.
- Equipe labellisée par la Fondation pour la Recherche Médicale, Paris, France.
- Laboratoire d'excellence du Globule Rouge GR-Ex, Université Paris Cité, Paris, France.
- Assistance Publique-Hôpitaux de Paris.Centre-Université Paris Cité, Hôpital Cochin, Laboratory of Hematology, Paris, France.
| |
Collapse
|
2
|
Danlos FX, Grajeda-Iglesias C, Durand S, Sauvat A, Roumier M, Cantin D, Colomba E, Rohmer J, Pommeret F, Baciarello G, Willekens C, Vasse M, Griscelli F, Fahrner JE, Goubet AG, Dubuisson A, Derosa L, Nirmalathasan N, Bredel D, Mouraud S, Pradon C, Stoclin A, Rozenberg F, Duchemin J, Jourdi G, Ellouze S, Levavasseur F, Albigès L, Soria JC, Barlesi F, Solary E, André F, Pène F, Ackerman F, Mouthon L, Zitvogel L, Marabelle A, Michot JM, Fontenay M, Kroemer G. Correction: Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis 2024; 15:142. [PMID: 38355585 PMCID: PMC10866964 DOI: 10.1038/s41419-024-06519-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/16/2024]
Affiliation(s)
- François-Xavier Danlos
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Claudia Grajeda-Iglesias
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U1138, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Sylvère Durand
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Allan Sauvat
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Mathilde Roumier
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Delphine Cantin
- Service d'Accueil des Urgences, AP-HP, Hôpital Hôtel-Dieu, 75004, Paris, France
| | - Emeline Colomba
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Julien Rohmer
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Fanny Pommeret
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Giulia Baciarello
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Christophe Willekens
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Marc Vasse
- Service de biologie clinique, Hôpital Foch, 92150, Suresnes, France
| | - Frank Griscelli
- Service de virologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Jean-Eudes Fahrner
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Anne-Gaëlle Goubet
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Agathe Dubuisson
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Lisa Derosa
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
| | | | - Delphine Bredel
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Séverine Mouraud
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Caroline Pradon
- Département de Biologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Annabelle Stoclin
- Département de Réanimation, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Flore Rozenberg
- Service de Virologie, AP-HP. Centre-Université de Paris, Hôpital Cochin, Paris, France
| | - Jérôme Duchemin
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
| | - Georges Jourdi
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
- Université de Paris, Innovative Therapies in Haemostasis, INSERM 1140, F-75006, Paris, France
| | - Syrine Ellouze
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
| | - Françoise Levavasseur
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
| | - Laurence Albigès
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | | | - Fabrice Barlesi
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France
| | - Eric Solary
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U1287, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Fabrice André
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U981, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Frédéric Pène
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
- Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, 75014, Paris, France
| | - Félix Ackerman
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Luc Mouthon
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
- Service de Médecine Interne, AP-HP, Hôpital Cochin, 75014, Paris, France
| | - Laurence Zitvogel
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
| | - Aurélien Marabelle
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
- Département d'Innovation Thérapeutique et des Essais Précoces, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Jean-Marie Michot
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Département d'Innovation Thérapeutique et des Essais Précoces, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Michaela Fontenay
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
| | - Guido Kroemer
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France.
- Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.
- Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, 75015, Paris, France.
- Suzhou Institute for Systems Biology, Chinese Academy of Sciences, Suzhou, China.
- Department of Women's and Children's Health, Karolinska University Hospital, 17176, Stockholm, Sweden.
| |
Collapse
|
3
|
Grelier A, Guérin O, Caillot F, Levavasseur F, Bénichou J, Caron F. Déterminants de la qualité de vie des personnels hospitaliers soignants et médicaux en contexte COVID : enquête en un CHU lors de la première vague. Infect Dis Now 2021. [PMCID: PMC8327585 DOI: 10.1016/j.idnow.2021.06.240] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
Introduction Matériels et méthodes Résultats Conclusion
Collapse
|
4
|
Smadja DM, Philippe A, Bory O, Gendron N, Beauvais A, Gruest M, Peron N, Khider L, Guerin CL, Goudot G, Levavasseur F, Duchemin J, Pene F, Cheurfa C, Szwebel TA, Sourdeau E, Planquette B, Hauw-Berlemont C, Hermann B, Gaussem P, Samama CM, Mirault T, Terrier B, Sanchez O, Rance B, Fontenay M, Diehl JL, Chocron R. Placental growth factor level in plasma predicts COVID-19 severity and in-hospital mortality. J Thromb Haemost 2021; 19:1823-1830. [PMID: 33830623 PMCID: PMC8250221 DOI: 10.1111/jth.15339] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/23/2020] [Revised: 02/17/2021] [Accepted: 03/25/2021] [Indexed: 12/20/2022]
Abstract
BACKGROUND Coronavirus disease 2019 (COVID-19) is a respiratory disease associated with vascular inflammation and endothelial injury. OBJECTIVES To correlate circulating angiogenic markers vascular endothelial growth factor A (VEGF-A), placental growth factor (PlGF), and fibroblast growth factor 2 (FGF-2) to in-hospital mortality in COVID-19 adult patients. METHODS Consecutive ambulatory and hospitalized patients with COVID-19 infection were enrolled. VEGF-A, PlGF, and FGF-2 were measured in each patient ≤48 h following admission. RESULTS The study enrolled 237 patients with suspected COVID-19: 208 patients had a positive diagnostic for COVID-19, of whom 23 were mild outpatients and 185 patients hospitalized after admission. Levels of VEGF-A, PlGF, and FGF-2 significantly increase with the severity of the disease (P < .001). Using a logistic regression model, we found a significant association between the increase of FGF-2 or PlGF and mortality (odds ratio [OR] 1.11, 95% confidence interval [CI; 1.07-1.16], P < .001 for FGF-2 and OR 1.07 95% CI [1.04-1.10], P < .001 for PlGF) while no association were found for VEGF-A levels. Receiver operating characteristic curve analysis was performed and we identified PlGF above 30 pg/ml as the best predictor of in-hospital mortality in COVID-19 patients. Survival analysis for PlGF confirmed its interest for in-hospital mortality prediction, by using a Kaplan-Meier survival curve (P = .001) and a Cox proportional hazard model adjusted to age, body mass index, D-dimer, and C-reactive protein (3.23 95% CI [1.29-8.11], P = .001). CONCLUSION Angiogenic factor PlGF is a relevant predictive factor for in-hospital mortality in COVID-19 patients. More than a biomarker, we hypothesize that PlGF blocking strategies could be a new interesting therapeutic approach in COVID-19.
Collapse
Affiliation(s)
- David M Smadja
- Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France
- Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Aurélien Philippe
- Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France
- Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Olivier Bory
- Université de Paris, Emergency Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Nicolas Gendron
- Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France
- Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Agathe Beauvais
- Université de Paris, Emergency Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Maxime Gruest
- Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France
- Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Nicolas Peron
- Université de Paris, Intensive Care Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Lina Khider
- Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Coralie L Guerin
- Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France
- Curie Institute, Cytometry Department, Paris, France
| | - Guillaume Goudot
- Université de Paris, Vascular Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Françoise Levavasseur
- Université de Paris, Institut Cochin, INSERM, Paris, France
- Hematology Department Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Jérome Duchemin
- Université de Paris, Institut Cochin, INSERM, Paris, France
- Hematology Department Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Frédéric Pene
- Internal Medicine Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Cherifa Cheurfa
- Intensive Care Medicine and Reanimation Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Tali-Anne Szwebel
- Internal Medicine Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Elise Sourdeau
- Emergency Unit, Hôpital Hôtel-Dieu, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Benjamin Planquette
- Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France
- Respiratory Medicine Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Caroline Hauw-Berlemont
- Université de Paris, Intensive Care Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Bertrand Hermann
- Université de Paris, Intensive Care Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Pascale Gaussem
- Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France
- Hematology Department and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Charles-Marc Samama
- Intensive Care Medicine and Reanimation Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Tristan Mirault
- Université de Paris, PARCC, INSERM, Paris, France
- Vascular Medicine Department, Assistance Publique - Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Benjamin Terrier
- Internal Medicine Department, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
- Université de Paris, PARCC, INSERM, Paris, France
| | - Olivier Sanchez
- Emergency Unit, Hôpital Hôtel-Dieu, Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Bastien Rance
- Université de Paris, Department of Medical Informatics, AP-HP, Georges Pompidou European Hospital, Paris, France
| | - Michaela Fontenay
- Université de Paris, Institut Cochin, INSERM, Paris, France
- Hematology Department Assistance Publique Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Jean-Luc Diehl
- Université de Paris, Innovative Therapies in Haemostasis, INSERM, Paris, France
- Intensive Care Unit and Biosurgical Research Lab (Carpentier Foundation), Assistance Publique - Hôpitaux de Paris-Centre (APHP-CUP), Paris, France
| | - Richard Chocron
- Université de Paris, PARCC, INSERM U970, Paris, France
- Emergency Department, AH-HP-Centre Université de Paris (APHP-CUP), Paris, France
| |
Collapse
|
5
|
Danlos FX, Grajeda-Iglesias C, Durand S, Sauvat A, Roumier M, Cantin D, Colomba E, Rohmer J, Pommeret F, Baciarello G, Willekens C, Vasse M, Griscelli F, Fahrner JE, Goubet AG, Dubuisson A, Derosa L, Nirmalathasan N, Bredel D, Mouraud S, Pradon C, Stoclin A, Rozenberg F, Duchemin J, Jourdi G, Ellouze S, Levavasseur F, Albigès L, Soria JC, Barlesi F, Solary E, André F, Pène F, Ackerman F, Mouthon L, Zitvogel L, Marabelle A, Michot JM, Fontenay M, Kroemer G. Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers. Cell Death Dis 2021; 12:258. [PMID: 33707411 PMCID: PMC7948172 DOI: 10.1038/s41419-021-03540-y] [Citation(s) in RCA: 87] [Impact Index Per Article: 29.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/24/2020] [Revised: 02/09/2021] [Accepted: 02/10/2021] [Indexed: 02/07/2023]
Abstract
The circulating metabolome provides a snapshot of the physiological state of the organism responding to pathogenic challenges. Here we report alterations in the plasma metabolome reflecting the clinical presentation of COVID-19 patients with mild (ambulatory) diseases, moderate disease (radiologically confirmed pneumonitis, hospitalization and oxygen therapy), and critical disease (in intensive care). This analysis revealed major disease- and stage-associated shifts in the metabolome, meaning that at least 77 metabolites including amino acids, lipids, polyamines and sugars, as well as their derivatives, were altered in critical COVID-19 patient's plasma as compared to mild COVID-19 patients. Among a uniformly moderate cohort of patients who received tocilizumab, only 10 metabolites were different among individuals with a favorable evolution as compared to those who required transfer into the intensive care unit. The elevation of one single metabolite, anthranilic acid, had a poor prognostic value, correlating with the maintenance of high interleukin-10 and -18 levels. Given that products of the kynurenine pathway including anthranilic acid have immunosuppressive properties, we speculate on the therapeutic utility to inhibit the rate-limiting enzymes of this pathway including indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase.
Collapse
Affiliation(s)
- François-Xavier Danlos
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Claudia Grajeda-Iglesias
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U1138, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Sylvère Durand
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Allan Sauvat
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Mathilde Roumier
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Delphine Cantin
- Service d'Accueil des Urgences, AP-HP, Hôpital Hôtel-Dieu, 75004, Paris, France
| | - Emeline Colomba
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Julien Rohmer
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Fanny Pommeret
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Giulia Baciarello
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Christophe Willekens
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Marc Vasse
- Service de biologie clinique, Hôpital Foch, 92150, Suresnes, France
| | - Frank Griscelli
- Service de virologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Jean-Eudes Fahrner
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Anne-Gaëlle Goubet
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Agathe Dubuisson
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
| | - Lisa Derosa
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
| | | | - Delphine Bredel
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Séverine Mouraud
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Caroline Pradon
- Département de Biologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Annabelle Stoclin
- Département de Réanimation, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Flore Rozenberg
- Service de Virologie, AP-HP. Centre-Université de Paris, Hôpital Cochin, Paris, France
| | - Jérôme Duchemin
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
| | - Georges Jourdi
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
- Université de Paris, Innovative Therapies in Haemostasis, INSERM 1140, F-75006, Paris, France
| | - Syrine Ellouze
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
| | - Françoise Levavasseur
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
| | - Laurence Albigès
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | | | - Fabrice Barlesi
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France
| | - Eric Solary
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U1287, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Fabrice André
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Département d'Oncologie Médicale, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- INSERM U981, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Frédéric Pène
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
- Service de Médecine Intensive et Réanimation, AP-HP, Hôpital Cochin, 75014, Paris, France
| | - Félix Ackerman
- Service de Médecine Interne, Hôpital Foch, 92150, Suresnes, France
| | - Luc Mouthon
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
- Service de Médecine Interne, AP-HP, Hôpital Cochin, 75014, Paris, France
| | - Laurence Zitvogel
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
| | - Aurélien Marabelle
- INSERM U1015, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Université Paris Saclay, Faculté de Médecine, 94270, Le Kremlin-Bicêtre, France
- Centre d'Investigation Clinique - Biothérapie, INSERM CICBT1428, 94800, Villejuif, France
- Département d'Innovation Thérapeutique et des Essais Précoces, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Jean-Marie Michot
- Département d'Hématologie, Gustave Roussy Cancer Campus, 94800, Villejuif, France
- Département d'Innovation Thérapeutique et des Essais Précoces, Gustave Roussy Cancer Campus, 94800, Villejuif, France
| | - Michaela Fontenay
- Service d'Hématologie Biologique, AP-HP, Centre-Université de Paris, Hôpital Cochin, 75014, Paris, France
- Université de Paris, Institut Cochin, CNRS UMR8104, INSERM U1016, 75006, Paris, France
| | - Guido Kroemer
- Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, 94800, Villejuif, France.
- Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, Université de Paris, Sorbonne Université, INSERM U1138, Institut Universitaire de France, Paris, France.
- Pôle de Biologie, Hôpital Européen Georges Pompidou, AP-HP, 75015, Paris, France.
- Suzhou Institute for Systems Biology, Chinese Academy of Sciences, Suzhou, China.
- Department of Women's and Children's Health, Karolinska University Hospital, 17176, Stockholm, Sweden.
| |
Collapse
|
6
|
Rajas F, Dentin R, Cannella Miliano A, Silva M, Raffin M, Levavasseur F, Gautier-Stein A, Postic C, Mithieux G. The absence of hepatic glucose-6 phosphatase/ChREBP couple is incompatible with survival in mice. Mol Metab 2020; 43:101108. [PMID: 33137488 PMCID: PMC7691719 DOI: 10.1016/j.molmet.2020.101108] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Revised: 10/27/2020] [Accepted: 10/28/2020] [Indexed: 02/06/2023] Open
Abstract
Objective Glucose production in the blood requires the expression of glucose-6 phosphatase (G6Pase), a key enzyme that allows glucose-6 phosphate (G6P) hydrolysis into free glucose and inorganic phosphate. We previously reported that the hepatic suppression of G6Pase leads to G6P accumulation and to metabolic reprogramming in hepatocytes from liver G6Pase-deficient mice (L.G6pc−/−). Interestingly, the activity of the transcription factor carbohydrate response element-binding protein (ChREBP), central for de novo lipid synthesis, is markedly activated in L.G6pc−/− mice, which consequently rapidly develop NAFLD-like pathology. In the current work, we assessed whether a selective deletion of ChREBP could prevent hepatic lipid accumulation and NAFLD initiation in L.G6pc−/− mice. Methods We generated liver-specific ChREBP (L.Chrebp−/−)- and/or G6Pase (L.G6pc−/−)-deficient mice using a Cre-lox strategy in B6.SACreERT2 mice. Mice were fed a standard chow diet or a high-fat diet for 10 days. Markers of hepatic metabolism and cellular stress were analysed in the liver of control, L. G6pc−/−, L. Chrebp−/− and double knockout (i.e., L.G6pc−/−.Chrebp−/−) mice. Results We observed that there was a dramatic decrease in lipid accumulation in the liver of L.G6pc−/−.Chrebp−/− mice. At the mechanistic level, elevated G6P concentrations caused by lack of G6Pase are rerouted towards glycogen synthesis. Importantly, this exacerbated glycogen accumulation, leading to hepatic water retention and aggravated hepatomegaly. This caused animal distress and hepatocyte damage, characterised by ballooning and moderate fibrosis, paralleled with acute endoplasmic reticulum stress. Conclusions Our study reveals the crucial role of the ChREBP-G6Pase duo in the regulation of G6P-regulated pathways in the liver. Hepatic deletion of both ChREBP and glucose-6 phosphatase collapses liver lipids. Double deletion leads to excessive glycogen storage and a liver swollen with water. Hepatic deletion of both ChREBP and glucose-6 phosphatase leads to death. Glucose-6 phosphate homeostasis in hepatocytes is a vital function.
Collapse
Affiliation(s)
- Fabienne Rajas
- Université Claude Bernard Lyon 1, Université de Lyon, INSERM UMR-1213, Lyon, France.
| | - Renaud Dentin
- Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France
| | | | - Marine Silva
- Université Claude Bernard Lyon 1, Université de Lyon, INSERM UMR-1213, Lyon, France
| | - Margaux Raffin
- Université Claude Bernard Lyon 1, Université de Lyon, INSERM UMR-1213, Lyon, France
| | | | | | - Catherine Postic
- Université de Paris, Institut Cochin, CNRS, INSERM, Paris, France
| | - Gilles Mithieux
- Université Claude Bernard Lyon 1, Université de Lyon, INSERM UMR-1213, Lyon, France
| |
Collapse
|
7
|
Iroz A, Montagner A, Benhamed F, Levavasseur F, Polizzi A, Anthony E, Régnier M, Fouché E, Lukowicz C, Cauzac M, Tournier E, Do-Cruzeiro M, Daujat-Chavanieu M, Gerbal-Chalouin S, Fauveau V, Marmier S, Burnol AF, Guilmeau S, Lippi Y, Girard J, Wahli W, Dentin R, Guillou H, Postic C. A Specific ChREBP and PPARα Cross-Talk Is Required for the Glucose-Mediated FGF21 Response. Cell Rep 2018; 21:403-416. [PMID: 29020627 PMCID: PMC5643524 DOI: 10.1016/j.celrep.2017.09.065] [Citation(s) in RCA: 86] [Impact Index Per Article: 14.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2016] [Revised: 08/15/2017] [Accepted: 09/20/2017] [Indexed: 02/03/2023] Open
Abstract
While the physiological benefits of the fibroblast growth factor 21 (FGF21) hepatokine are documented in response to fasting, little information is available on Fgf21 regulation in a glucose-overload context. We report that peroxisome-proliferator-activated receptor α (PPARα), a nuclear receptor of the fasting response, is required with the carbohydrate-sensitive transcription factor carbohydrate-responsive element-binding protein (ChREBP) to balance FGF21 glucose response. Microarray analysis indicated that only a few hepatic genes respond to fasting and glucose similarly to Fgf21. Glucose-challenged Chrebp−/− mice exhibit a marked reduction in FGF21 production, a decrease that was rescued by re-expression of an active ChREBP isoform in the liver of Chrebp−/− mice. Unexpectedly, carbohydrate challenge of hepatic Pparα knockout mice also demonstrated a PPARα-dependent glucose response for Fgf21 that was associated with an increased sucrose preference. This blunted response was due to decreased Fgf21 promoter accessibility and diminished ChREBP binding onto Fgf21 carbohydrate-responsive element (ChoRE) in hepatocytes lacking PPARα. Our study reports that PPARα is required for the ChREBP-induced glucose response of FGF21. Fgf21 is a unique hepatic gene inducible by both catabolic and anabolic signals The ChREBP-mediated induction of Fgf21 in hepatocytes requires PPARα Loss of PPARα impairs Fgf21 promoter accessibility at the ChoRE PPARα is required for the control of sucrose preference in vivo
Collapse
Affiliation(s)
- Alison Iroz
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Alexandra Montagner
- Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, France
| | - Fadila Benhamed
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Françoise Levavasseur
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Arnaud Polizzi
- Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, France
| | - Elodie Anthony
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Marion Régnier
- Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, France
| | - Edwin Fouché
- Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, France
| | - Céline Lukowicz
- Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, France
| | - Michèle Cauzac
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Emilie Tournier
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Marcio Do-Cruzeiro
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Martine Daujat-Chavanieu
- INSERM, U1183, Institute for Regenerative Medicine and Biotherapy, Montpellier, France; Université de Montpellier, UMR 1183, Montpellier, France; CHU Montpellier, Institute for Regenerative Medicine and Biotherapy, Montpellier, France
| | - Sabine Gerbal-Chalouin
- INSERM, U1183, Institute for Regenerative Medicine and Biotherapy, Montpellier, France; Université de Montpellier, UMR 1183, Montpellier, France; CHU Montpellier, Institute for Regenerative Medicine and Biotherapy, Montpellier, France
| | - Véronique Fauveau
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Solenne Marmier
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Anne-Françoise Burnol
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Sandra Guilmeau
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Yannick Lippi
- Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, France
| | - Jean Girard
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France
| | - Walter Wahli
- Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, France; Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore; Center for Integrative Genomics, University of Lausanne, Genopode Building, Lausanne 1015, Switzerland
| | - Renaud Dentin
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France.
| | - Hervé Guillou
- Toxalim, Université de Toulouse, INRA, ENVT, INP-Purpan, UPS, Toulouse 31027, France.
| | - Catherine Postic
- INSERM U1016, Institut Cochin, Paris 75014, France; CNRS UMR 8104, Paris 75014, France; University of Paris Descartes, Sorbonne Paris Cité, Paris 75005, France.
| |
Collapse
|
8
|
Le Gouas A, Ahmar M, Dememe V, Levavasseur F, Batouche C, Lefèbvre C, Caron F, Gueit I. COL INF-03 - Améliorer le repas, épreuve de tous les dangers pour les patients alités pour spondylodiscite. Med Mal Infect 2016. [DOI: 10.1016/s0399-077x(16)30584-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
9
|
Le Gouas A, Saussaye V, Poulet F, Levavasseur F, Laforest B, Caron F, Gueit I. U-06: Qualité des soins en infectiologie : les limites des chambres à lits multiples. Med Mal Infect 2014. [DOI: 10.1016/s0399-077x(14)70355-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
10
|
Ulmann L, Levavasseur F, Avignone E, Peyroutou R, Hirbec H, Audinat E, Rassendren F. Involvement of P2X4 receptors in hippocampal microglial activation after status epilepticus. Glia 2013; 61:1306-19. [PMID: 23828736 DOI: 10.1002/glia.22516] [Citation(s) in RCA: 82] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/27/2012] [Revised: 04/02/2013] [Accepted: 04/05/2013] [Indexed: 11/09/2022]
Abstract
Within the central nervous system, functions of the ATP-gated receptor-channel P2X4 (P2X4R) are still poorly understood, yet P2X4R activation in neurons and microglia coincides with high or pathological neuronal activities. In this study, we investigated the potential involvement of P2X4R in microglial functions in a model of kainate (KA)-induced status epilepticus (SE). We found that SE was associated with an induction of P2X4R expression in the hippocampus, mostly localized in activated microglial cells. In P2X4R-deficient mice, behavioral responses during KA-induced SE were unaltered. However, 48h post SE specific features of microglial activation, such as cell recruitment and upregulation of voltage-dependent potassium channels were impaired in P2X4R-deficient mice, whereas the expression and function of other microglial purinergic receptors remained unaffected. Consistent with the role of P2X4R in activity-dependent degenerative processes, the CA1 area was partially protected from SE-induced neuronal death in P2X4R-deficient mice compared with wild-type animals. Our findings demonstrate that P2X4Rs are brought into play during neuronal hyperexcitability and that they control specific aspects of microglial activation. Our results also suggest that P2X4Rs contribute to excitotoxic damages by regulating microglial activation.
Collapse
Affiliation(s)
- Lauriane Ulmann
- Institut de Génomique Fonctionnelle, Labex ICST, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 5203, Université Montpellier, Montpellier, France.
| | | | | | | | | | | | | |
Collapse
|
11
|
Menteyne A, Levavasseur F, Audinat E, Avignone E. Predominant functional expression of Kv1.3 by activated microglia of the hippocampus after Status epilepticus. PLoS One 2009; 4:e6770. [PMID: 19707551 PMCID: PMC2727945 DOI: 10.1371/journal.pone.0006770] [Citation(s) in RCA: 41] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2009] [Accepted: 07/31/2009] [Indexed: 12/26/2022] Open
Abstract
Background Growing evidence indicates that the functional state of microglial cells differs according to the pathological conditions that trigger their activation. In particular, activated microglial cells can express sets of Kv subunits which sustain delayed rectifying potassium currents (Kdr) and modulate differently microglia proliferation and ability to release mediators. We recently reported that hippocampal microglia is in a particular activation state after a status epilepticus (SE) and the present study aimed at identifying which of the Kv channels are functionally expressed by microglia in this model. Methodology/Principal Findings SE was induced by systemic injection of kainate in CX3CR1eGFP/+ mice and whole cell recordings of fluorescent microglia were performed in acute hippocampal slices prepared 48 h after SE. Microglia expressed Kdr currents which were characterized by a potential of half-maximal activation near −25 mV, prominent steady-state and cumulative inactivations. Kdr currents were almost abolished by the broad spectrum antagonist 4-Aminopyridine (1 mM). In contrast, tetraethylammonium (TEA) at a concentration of 1 mM, known to block Kv3.1, Kv1.1 and 1.2 subunits, only weakly reduced Kdr currents. However, at a concentration of 5 mM which should also affect Kv1.3 and 1.6, TEA inhibited about 30% of the Kdr conductance. Alpha-dendrotoxin, which selectively inhibits Kv1.1, 1.2 and 1.6, reduced only weakly Kdr currents, indicating that channels formed by homomeric assemblies of these subunits are not important contributors of Kdr currents. Finally, agitoxin-2 and margatoxin strongly inhibited the current. Conclusions/Significance These results indicate that Kv1.3 containing channels predominantly determined Kdr currents in activated microglia after SE.
Collapse
Affiliation(s)
- Alexis Menteyne
- Institut National de la Santé et de la Recherche Médicale, Unité 603, Paris, France
- Université Paris Descartes, Paris, France
- Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8154, Paris, France
| | - Françoise Levavasseur
- Institut National de la Santé et de la Recherche Médicale, Unité 603, Paris, France
- Université Paris Descartes, Paris, France
- Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8154, Paris, France
| | - Etienne Audinat
- Institut National de la Santé et de la Recherche Médicale, Unité 603, Paris, France
- Université Paris Descartes, Paris, France
- Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8154, Paris, France
- * E-mail:
| | - Elena Avignone
- Institut National de la Santé et de la Recherche Médicale, Unité 603, Paris, France
- Université Paris Descartes, Paris, France
- Centre National de la Recherche Scientifique, Unité Mixte de Recherche 8154, Paris, France
| |
Collapse
|
12
|
Levavasseur F, Miyadera H, Sirois J, Tremblay ML, Kita K, Shoubridge E, Hekimi S. Ubiquinone is necessary for mouse embryonic development but is not essential for mitochondrial respiration. J Biol Chem 2001; 276:46160-4. [PMID: 11585841 DOI: 10.1074/jbc.m108980200] [Citation(s) in RCA: 112] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
Ubiquinone (UQ) is a lipid found in most biological membranes and is a co-factor in many redox processes including the mitochondrial respiratory chain. UQ has been implicated in protection from oxidative stress and in the aging process. Consequently, it is used as a dietary supplement and to treat mitochondrial diseases. Mutants of the clk-1 gene of the nematode Caenorhabditis elegans are fertile and have an increased life span, although they do not produce UQ but instead accumulate a biosynthetic intermediate, demethoxyubiquinone (DMQ). DMQ appears capable to partially replace UQ for respiration in vivo and in vitro. We have produced a vertebrate model of cells and tissues devoid of UQ by generating a knockout mutation of the murine orthologue of clk-1 (mclk1). We find that mclk1-/- embryonic stem cells and embryos accumulate DMQ instead of UQ. As in the nematode mutant, the activity of the mitochondrial respiratory chain of -/- embryonic stem cells is only mildly affected (65% of wild-type oxygen consumption). However, mclk1-/- embryos arrest development at midgestation, although earlier developmental stages appear normal. These findings indicate that UQ is necessary for vertebrate embryonic development but suggest that mitochondrial respiration is not the function for which UQ is essential when DMQ is present.
Collapse
Affiliation(s)
- F Levavasseur
- Department of Biology, McGill University, 1205 Avenue Dr. Penfield, Montréal, Québec H3A 1B1, Canada
| | | | | | | | | | | | | |
Collapse
|
13
|
Jiang N, Levavasseur F, McCright B, Shoubridge EA, Hekimi S. Mouse CLK-1 is imported into mitochondria by an unusual process that requires a leader sequence but no membrane potential. J Biol Chem 2001; 276:29218-25. [PMID: 11387338 DOI: 10.1074/jbc.m103686200] [Citation(s) in RCA: 34] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022] Open
Abstract
clk-1 has been identified and characterized in the nematode Caenorhabditis elegans as a gene that affects the rates, regularity, and synchrony of physiological processes. The CLK-1 protein is mitochondrial and is required for ubiquinone biosynthesis in yeast and in worms, but its biochemical function remains unclear. We have studied the expression of murine mclk1 in a variety of tissues, and we find that the pattern of mclk1 mRNA accumulation closely resembles that of mitochondrial genes involved in oxidative phosphorylation. The pattern of protein accumulation, however, is sharply distinct in some tissues; mCLK1 appears relatively enriched in the gut and depleted in the nervous tissue. We also show that mCLK1 is synthesized as a preprotein that is imported into the mitochondrial matrix, where a leader sequence is cleaved off and the protein becomes loosely associated with the inner membrane. However, in contrast to all known mitochondrial proteins that contain a cleavable pre-sequence, the import of mCLK1 does not require a mitochondrial membrane potential.
Collapse
Affiliation(s)
- N Jiang
- Department of Biology, McGill University, H3A 1B1, Montréal, Québec, Canada
| | | | | | | | | |
Collapse
|
14
|
Levavasseur F, Zhu Q, Julien JP. No requirement of alpha-internexin for nervous system development and for radial growth of axons. Brain Res Mol Brain Res 1999; 69:104-12. [PMID: 10350642 DOI: 10.1016/s0169-328x(99)00104-7] [Citation(s) in RCA: 50] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Alpha-Internexin is a type IV intermediate filament protein that is expressed abundantly in neurons during development of the peripheral and central nervous systems as well as in few neurons of the adult central nervous system. It has been suggested that alpha-internexin may act as a scaffold for the formation of neuronal intermediate filaments during early development. In addition, recent reports suggest that alpha-internexin could play a major role in two degenerative neurological disorders. We report here an analysis of mice with a targeted disruption of alpha-internexin gene. Unexpectedly, alpha-internexin -/- mice developed normally and did not exhibit overt phenotypes. Moreover, the absence of alpha-internexin did not interfere with neurite extension of cultured DRG neurons. The number and caliber of L4 ventral root axons remained unchanged in alpha-internexin -/- mice. In the retina, alpha-internexin begins to be expressed in retinal ganglion cells when their first axons reach the optic chiasma. Using HRP tracer, we show that the projection pattern of the RGC axons is not modified by the absence of alpha-internexin. Electron microscopy did not reveal significant differences in axonal calibers, in myelination of axons and in neurofilament structures between alpha-internexin -/- and control mice during development and at adult stage. These data indicate that alpha-internexin is not required for the polymerization of neurofilament in vivo. Mice deficient for both alpha-internexin and neurofilament light chain (NF-L) exhibited no over phenotypes as well. No intermediate filament structures were detectable in optic nerve of alpha-internexin -/-; NF-L -/- mice. Ours results do not support the hypothesis of a role for type IV intermediate filaments in axonal outgrowth during development of nervous system.
Collapse
Affiliation(s)
- F Levavasseur
- Centre for Research in Neuroscience, McGill University, The Montreal General Hospital Research Institute, L12-218, 1650 Cedar Avenue, Montreal, Quebec, Canada
| | | | | |
Collapse
|
15
|
Zhu Q, Lindenbaum M, Levavasseur F, Jacomy H, Julien JP. Disruption of the NF-H gene increases axonal microtubule content and velocity of neurofilament transport: relief of axonopathy resulting from the toxin beta,beta'-iminodipropionitrile. J Cell Biol 1998; 143:183-93. [PMID: 9763430 PMCID: PMC2132812 DOI: 10.1083/jcb.143.1.183] [Citation(s) in RCA: 112] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/05/1998] [Revised: 06/25/1998] [Indexed: 11/22/2022] Open
Abstract
To investigate the role of the neurofilament heavy (NF-H) subunit in neuronal function, we generated mice bearing a targeted disruption of the gene coding for the NF-H subunit. Surprisingly, the lack of NF-H subunits had little effect on axonal calibers and electron microscopy revealed no significant changes in the number and packing density of neurofilaments made up of only the neurofilament light (NF-L) and neurofilament medium (NF-M) subunits. However, our analysis of NF-H knockout mice revealed an approximately 2.4-fold increase of microtubule density in their large ventral root axons. This finding was further corroborated by a corresponding increase in the ratio of assembled tubulin to NF-L protein in insoluble cytoskeletal preparations from the sciatic nerve. Axonal transport studies carried out by the injection of [35S]methionine into spinal cord revealed an increased transport velocity of newly synthesized NF-L and NF-M proteins in motor axons of NF-H knockout mice. When treated with beta,beta'-iminodipropionitrile (IDPN), a neurotoxin that segregates microtubules and retards neurofilament transport, mice heterozygous or homozygous for the NF-H null mutation did not develop neurofilamentous swellings in motor neurons, unlike normal mouse littermates. These results indicate that the NF-H subunit is a key mediator of IDPN-induced axonopathy.
Collapse
Affiliation(s)
- Q Zhu
- Centre for Research in Neuroscience, McGill University, The Montreal General Hospital Research Institute, Montréal, Qúebec, Canada H3G 1A4
| | | | | | | | | |
Collapse
|
16
|
Levavasseur F, Mandemakers W, Visser P, Broos L, Grosveld F, Zivkovic D, Meijer D. Comparison of sequence and function of the Oct-6 genes in zebrafish, chicken and mouse. Mech Dev 1998; 74:89-98. [PMID: 9651490 DOI: 10.1016/s0925-4773(98)00067-7] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
To examine the role of the Oct-6 gene in Schwann cell differentiation we have cloned and characterized the chicken and zebrafish homologues of the mouse Oct-6 gene. While highly homologous in the Pit1-Oct1/2-Unc86 (POU) domain, sequence similarities are limited outside this domain. Both genes are intronless and both proteins lack the amino acid repeats that are a characteristic feature of the mammalian Oct-6 proteins. However as in mammals, the aminoterminal parts of the chicken and zebrafish Oct-6 proteins are essential for transactivation of octamer containing promoters. By immunohistochemistry we have found that the chicken Oct-6 protein is expressed in late embryonic ensheathing Schwann cells of the sciatic nerve and is rapidly downregulated when myelination proceeds. This expression profile in glial cells is identical to that in the mouse and rat. Furthermore the zebrafish Oct-6 homolog is expressed in the posterior lateral nerve at a time when it contains actively myelinating Schwann cells. Thus despite extensive primary sequence divergence among the vertebrate Oct-6 proteins, the expression of the chicken and zebrafish Oct-6 proteins is consistent with the notion that Oct-6 functions as a 'competence factor' in promyelin cells to execute the myelination program.
Collapse
Affiliation(s)
- F Levavasseur
- MGC, Dept. of Cell Biology and Genetics, Erasmus University Rotterdam, P.O. Box 1738, The Netherlands
| | | | | | | | | | | | | |
Collapse
|
17
|
Christa L, Carnot F, Simon MT, Levavasseur F, Stinnakre MG, Lasserre C, Thepot D, Clement B, Devinoy E, Brechot C. HIP/PAP is an adhesive protein expressed in hepatocarcinoma, normal Paneth, and pancreatic cells. Am J Physiol 1996; 271:G993-1002. [PMID: 8997243 DOI: 10.1152/ajpgi.1996.271.6.g993] [Citation(s) in RCA: 39] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Human hepatocarcinoma-intestine-pancreas (HIP) cDNA, isolated from a hepatocellular carcinoma, encodes a C-type lectin. According to published cDNA sequences, HIP protein is identical to human pancreatitis-associated protein (PAP). In these sequences, a putative signal peptide and the carbohydrate recognition domain (CRD) can be recognized. In the present study, we established transgenic mice to drive the production of soluble recombinant HIP/PAP protein in the milk of lactating animals; using this model, we showed that HIP/PAP protein was secreted after suitable cleavage of the potential signal peptide. Moreover, we also produced HIP/PAP protein by Escherichia coli cultures performed to generate specific antibodies. These antibodies enabled the detection of HIP/PAP protein in normal intestine and pancreas (both in endocrine and exocrine cells), e.g., intestinal neuroendocrine and Paneth cells, pancreatic islets of Langerhans, and acinar cells. HIP/PAP protein was also identified in the cytoplasm of tumoral hepatocytes but not in nontumoral hepatocytes. Finally, HIP/PAP protein activity was tested and we showed that HIP/PAP induced the adhesion of rat hepatocytes and bound strongly to extracellular matrix proteins (laminin-1, fibronectin), less strongly to type I and IV collagen, and not at all to heparan sulfate proteoglycan. In conclusion, these results showed that HIP/PAP protein was matured on secretion. We also demonstrated that HIP/PAP protein was specifically expressed in hepatocarcinoma cells and interacted with rat hepatocytes and the extracellular matrix. Taken overall, these results suggest that HIP/PAP protein may be of potential importance to liver cell differentiation/proliferation.
Collapse
Affiliation(s)
- L Christa
- Institut National de la Santé et de la Recherche Médicale Unité 370, Centre Hospitalier Universitaire Necker, Paris, France
| | | | | | | | | | | | | | | | | | | |
Collapse
|
18
|
Levavasseur F, Liétard J, Ogawa K, Théret N, Burbelo PD, Yamada Y, Guillouzo A, Clément B. Expression of laminin gamma 1 cultured hepatocytes involves repeated CTC and GC elements in the LAMC1 promoter. Biochem J 1996; 313 ( Pt 3):745-52. [PMID: 8611150 PMCID: PMC1216973 DOI: 10.1042/bj3130745] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/31/2023]
Abstract
Laminin gamma 1 chain is present in all basement membranes and is expressed at high levels in various diseases, such as hepatic fibrosis. We have identified cis- and trans-acting elements involved in the regulation of this gene in normal rat liver, as well as in hepatocyte primary cultures and hepatoma cell lines. Northern-blot analyses showed that laminin gamma 1 mRNA was barely detectable in freshly isolated hepatocytes and expressed at high levels in hepatocyte primary cultures, as early as 4 h after liver dissociation. Actinomycin D and cycloheximide treatment in vivo and in vitro indicated that laminin gamma 1 overexpression in cultured hepatocytes was under the control of transcriptional mechanisms. Transfection of deletion mutants of the 5' flanking region of murine LAMC1 gene in hepatoma cells that constitutively express laminin gamma 1 indicated that regulatory elements were located between -594 bp and -94 bp. This segment included GC- and CTC-containing motifs. Gel-shift analyses showed that two complexes were resolved with different affinity for the CTC sequence depending on the location of the GC box. The pattern of complex formation with nuclear factors from freshly isolated and cultured hepatocytes was different from that obtained with total liver and similar to that with hepatoma cells. Southwestern analysis indicated that several polypeptides bound the CTC-rich sequence. Affinity chromatography demonstrated that A M(r) 60,000 polypeptide was a major protein binding to the CTC motif. This polypeptide is probably involved in the transcriptional activation of various proto-oncogenes and extracellular matrix genes that are expressed at high levels in both hepatoma cells and early hepatocyte cultures.
Collapse
Affiliation(s)
- F Levavasseur
- Institut National de la Santé et de la Recherche Médicale, Unité de Recherches Hépatologiques U-49, CHRU Pontchaillou, Rennes, France
| | | | | | | | | | | | | | | |
Collapse
|
19
|
Levavasseur F, Burbelo PD, Cariou S, Liétard J, Yamada Y, Clément B. Nuclear recruitment of A1p145 subunit of replication factor C in the early G1 phase of the cell cycle in Faza 567 hepatoma cell line and hepatocyte primary cultures. FEBS Lett 1995; 363:132-6. [PMID: 7729533 DOI: 10.1016/0014-5793(95)00305-s] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
Using a combination of immunoprecipitation and Western blotting with Faza 567 hepatoma cell extracts revealed that the large subunit of replication factor C (A1p145; mRFC140) was in a complex with proliferating cell nuclear antigen (PCNA). Western blotting showed that A1p145 was more abundant in nuclear extracts from butyrate-treated hepatoma cells which blocks the cells in the G1 phase of the cell cycle than from routinely cultured cells. Indirect immunoperoxidase analysis of G1 blocked Faza hepatoma cells localized A1p145 protein predominantly in the nucleoli. When hepatoma cells were stimulated to progress toward the S phase, A1p145 protein was then observed in both the cytoplasm and the nucleoplasm of these cells. Studies with early cultured normal hepatocytes which are progressing from G0 towards G1, also showed a nucleolus distribution for A1p145. This is the first demonstration in mammalian cells that the large subunit of replication factor C is associated with PCNA in the nucleus and that its distribution within cells changes during the cell cycle.
Collapse
Affiliation(s)
- F Levavasseur
- Unité de Recherches Hépatologiques U 49 de l'INSERM, CHRU Pontchaillou, Rennes, France
| | | | | | | | | | | |
Collapse
|
20
|
Levavasseur F, Loréal O, Liétard J, Théret N, L'Helgoualc'h A, Guillouzo A, Clément B. Basement membrane gene expression in the liver. J Hepatol 1995; 22:10-9. [PMID: 7665841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/04/2022]
Affiliation(s)
- F Levavasseur
- Unité de Recherches Hépatologiques, INSERM U-49, CHRU Pontchaillou, Rennes-France
| | | | | | | | | | | | | |
Collapse
|
21
|
Levavasseur F, Mayer U, Guillouzo A, Clement B. Influence of nidogen complexed or not with laminin on attachment, spreading, and albumin and laminin B2 mRNA levels of rat hepatocytes. J Cell Physiol 1994; 161:257-66. [PMID: 7962110 DOI: 10.1002/jcp.1041610210] [Citation(s) in RCA: 13] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
Nidogen/entactin is a Mr = 150,000 glycoprotein which is present within basement membranes in a noncovalent stable complex with laminin. We have studied the effects of nidogen/entactin complexed or not with laminin on attachment, spreading, and functions of adult rat hepatocytes in primary culture. Freshly isolated hepatocytes attached on either recombinant or EHS-derived nidogen, although to a lesser extent than on laminin/nidogen complex, laminin, and E8 and P1 fragments of laminin. Hepatocytes bound on a nidogen fragment bearing the N-terminal and rod-like domains but not on either the N-terminal globules or the rod-like domain which contains a RGD sequence. Attachment of hepatocytes on nidogen and laminin/nidogen complex was inhibited by anti-beta 1 integrin antibodies. Hepatocytes remained rounded on nidogen and laminin, whereas they rapidly spread on laminin/nidogen complex and collagen IV. Nidogen, laminin, and laminin/nidogen complex transiently maintained high steady-state albumin mRNA levels in cultured hepatocytes, but a decrease in albumin mRNA content was observed after 24 h, independently of the substrates. Actinomycin D and cycloheximide treatment indicated that the transient effect of these substrates on albumin expression was related to post-transcriptional mechanisms. Laminin B2 mRNAs were not detectable in freshly isolated hepatocytes but were expressed in 4 h hepatocyte cultures. After 24 h, a dramatic increase in the steady-state level of laminin B2 mRNA was found in hepatocytes cultured on nidogen and laminin/nidogen complex. This effect was slightly prevented in hepatocytes plated on laminin. These results show that interactions of hepatocytes with nidogen/entactin in vitro result only in a transient modulation of hepatocyte functions.
Collapse
Affiliation(s)
- F Levavasseur
- Unité de Recherches Hépatologiques, INSERM U-49, Hôpital Pontchaillou, Rennes, France
| | | | | | | |
Collapse
|
22
|
Loréal O, Levavasseur F, Fromaget C, Gros D, Guillouzo A, Clément B. Cooperation of Ito cells and hepatocytes in the deposition of an extracellular matrix in vitro. Am J Pathol 1993; 143:538-44. [PMID: 8342601 PMCID: PMC1887016] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/30/2023]
Abstract
Cellular and molecular mechanisms involved in the deposition of extracellular matrix components in both normal and fibrotic liver are still poorly understood. We have investigated the influence of cooperation between Ito cells and hepatocytes in matrix deposition in vitro. Immunoprecipitation of radiolabeled proteins from media of 5-day-old Ito cell primary cultures showed that these cells secreted high levels of the major basement membrane components, ie, collagen IV, laminin, and entactin/nidogen. By immunocytochemistry, precursors of basement membrane components were found intracellularly, but only scarce deposits were seen around the cells. When hepatocytes were added to 2-day-old Ito cell primary cultures, they established close contacts with Ito cells in less than 24 hours and expressed ZO-1, a tight junction-associated protein not detectable in standard hepatocyte culture. Cytochemistry analysis revealed an abundant extracellular matrix deposited over hepatocyte cords and between hepatocytes and Ito cells. Immunocytochemistry studies showed that this matrix contained laminin, fibronectin, and collagens proIII and IV. These data indicate that a high level of matrix protein synthesis by liver cells in vitro is not sufficient to induce extracellular matrix deposition, and that cell-cell interactions are strongly involved in this process. Hepatocyte/Ito cell co-culture, which may reflect the actual situation in vivo, represents a useful tool for studying liver fibrogenesis.
Collapse
Affiliation(s)
- O Loréal
- Unité de Recherches Hépatologiques, INSERM U-49, Hôpital Pontchaillou, Rennes, France
| | | | | | | | | | | |
Collapse
|
23
|
Abstract
Treatment of hepatic fibrosis by simple and inexpensive therapies is a new challenge for the near future. Hepatic fibrosis which may lead to cirrhosis, is indeed associated with most chronic liver diseases and affects millions of people. During the last decade, major breakthroughs have been accomplished in the field of hepatic fibrosis including the discovery of key components of the extracellular matrix, the cellular origin of most matrix proteins, the molecular mechanisms involved in their synthesis and degradation, and the role of cytokines in fibrogenesis. Most of this progress came from the development of new techniques including in vitro model systems which have proven useful for investigating the molecular bases of fibrogenesis. From basic research to clinical application, two major fields are now actively explored: the search for reliable serum markers of fibrogenesis and the discovery of drugs that prevent cirrhosis. A recent approach to treat hepatic fibrosis is to use cytokines, e.g. interferons, that modulate extracellular matrix synthesis.
Collapse
Affiliation(s)
- B Clément
- Institut National de la Santé et de la Recherche Médicale, Unité de Recherches Hépatologiques, INSERM U-49, Hôpital Pontchaillou, Rennes, France
| | | | | | | |
Collapse
|
24
|
Abstract
The lipocyte is an important source of laminin in the normal liver. We have investigated the expression of the 3 chains of laminin in isolated rat lipocytes. Both B1 and B2 chains, but not A, were found in medium from 5-day-old lipocyte primary cultures by immunoblotting and immunoprecipitation of 35S-labeled proteins after reducing SDS-polyacrylamide gel electrophoresis. An additional polypeptide of Mr = 380,000 was identified by immunoprecipitation. Under non-reducing conditions only one Mr = 900,000 band was revealed. High levels of B1 and B2 mRNAs were also demonstrated in 5-day-old cultured lipocytes while at the time of seeding, only B2 chain mRNAs were clearly detectable. A chain mRNA was constantly absent. These results suggest that lipocytes produce a variant form of laminin in primary culture and that the Mr = 380,000 polypeptide could be unrelated to the A chain of laminin.
Collapse
Affiliation(s)
- O Loreal
- Unité de Recherches Hépatologiques U 49 de l'INSERM, Hôpital de Pontchaillou, Rennes, France
| | | | | | | | | | | |
Collapse
|
25
|
Mousques T, Levavasseur F. [Suture technics and their application in periodontal surgery]. Actual Odontostomatol (Paris) 1989; 43:579-608. [PMID: 2699700] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
On account of the diversity of the periodontal therapy, the operator must be able to use for each interventions, the adapted suture technic. This article studies the different knots, modalities and sutures. These basics elements are then considered in different surgical case types. This study emphasizes that usually we dispose of several technics for each type of periodontal surgery. The clinician must choose in function of the nature of the material that he uses, as well as his experience, and his skill.
Collapse
|
26
|
Mousques T, Levavasseur F. [Surgical sutures. Principles and materials]. Actual Odontostomatol (Paris) 1989; 42:367-81. [PMID: 2699695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Abstract
This article begins by a brief review of the advantages and modalities of the sutures. Then, the choice of the instrumentation (needle-holders, pliers and scissors) will be discussed. The suture material by itself (needles, threads) is studied. A description of the physical and biological properties of the different threads allows their comparison. The author's choice is the conclusion of this paper.
Collapse
|
27
|
Doukhan JY, Kleinfinger S, Krief G, Levavasseur F. [Update on clasps]. Cah Prothese 1988:48-64. [PMID: 3077767] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
28
|
Lestradet H, Papoz L, Hellouin de Menibus C, Levavasseur F, Besse J, Billaud L, Battistelli F, Tric P, Lestradet F. Long-term study of mortality and vascular complications in juvenile-onset (type I) diabetes. Diabetes 1981; 30:175-9. [PMID: 7202860 DOI: 10.2337/diab.30.3.175] [Citation(s) in RCA: 39] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/24/2023]
Abstract
A cohort of 372 insulin-dependent diabetic children, diagnosed between October 1949 and December 1960, were followed-up until December 1976 by the same team of physicians. At the time of diagnosis all patients were under 16 yr of age and were given standardized treatment which did not change from 1949 to 1976. The therapy consisted of daily insulin adjustment based on clinical assessment, the degree of physical activity, and the results of semi-quantitative urine tests for sugar and ketone bodies. These tests were systematically performed before breakfast, lunch, and dinner. Diet was normal, unmeasured, rich in carbohydrates (approximately 60%), and quantitatively unrestricted unless the patient was overweight. Rates for mortality and for the principal complications among this cohort were computed by the actuarial method. During the 26 yr of study, 26 deaths occurred, 16 of which were directly connected with diabetes. After 16 yr of follow-up, rates of proteinuria and hypertension were 4% and 2.1% respectively. The incidence of retinopathy reached 27%, including 1.5% proliferative retinopathy. After 26 yr, the rates rose to 14% for proteinuria, 16% for hypertension, and 85% for retinopathy, including 18% in the proliferative phase.
Collapse
|
29
|
Houdent C, Gruber D, Levavasseur F, Wolf LM, Joram F, Le Bihan G, Bourreille J. [Iatrogenic disease due to amiloride-hydrochlorothiazide combination. 12 cases]. Ann Med Interne (Paris) 1976; 127:628-31. [PMID: 1008389] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
|